Vigilant Biosciences Debuts the Revolutionary BeVigilant OraFusion System in the UK

Vigilant Biosciences, Inc. (“Vigilant”), an innovator and creator of solutions aimed at facilitating the early detection of oral cancer, is proud to announce the launch of its transformative product, the BeVigilant OraFusion System, in the United Kingdom.

The BeVigilant OraFusion System stands out as an innovative device in the oral cancer domain, serving as a critical tool in oral cancer detection by identifying specific salivary biomarkers and integrating intelligent software to evaluate clinical risk factors. Detecting oral cancer in its infancy, particularly during Stage 1 or Stage 2, can dramatically improve outcomes, increasing survival rates to an impressive 90%. The current survival rate for oral cancer is 50%, predominantly due to delayed detection and intervention.

Despite oral cancer often presenting early symptoms, current dental screening limitations hinder early diagnosis. Healthcare practitioners, while diligent, may find early malignancy identification challenging, occasionally defaulting to a cautious approach. Late-stage diagnoses often necessitate extensive surgery, impacting quality of life. However, technological advancements in diagnostic methods, like the BeVigilant OraFusion System, empower practitioners to enhance early detection and dramatically improve their accuracy in assessing patients.

“Our mission revolves around elevating survival outcomes in oral cancer through early detection,” expressed Bill Brodie, CEO of Vigilant Biosciences. “The introduction of the BeVigilant OraFusion System to the UK market is a manifestation of our mission, to save lives through early detection, bringing renewed hope to those impacted by this disease.”

In its ongoing battle against oral cancer, Vigilant Biosciences perpetuates its commitment to developing straightforward, accurate and economical solutions, empowering healthcare practitioners to transform lives through timely intervention. For additional information about Vigilant Biosciences and its innovative products, please visit www.vigilantbiosciences.com .

Note: The BeVigilant OraFusion System is not available for sale in the U.S.

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.